Sign in

CIK 0001281895

  • Non-accelerated filer
  • Smaller reporting company

ROCKET PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RCKT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 646-440-9100
Business address
350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY, 10118
Former names
INOTEK PHARMACEUTICALS CORP
  1. 4 Open-market sale See Remarks sold 2,545 shares at $2.98 ($7,592)
  2. 4 Open-market sale See Remarks sold 1,086 shares at $2.98 ($3,240)
  3. 4 Open-market sale CEO sold 6,276 shares at $2.98 ($18,721)
  4. 4 Open-market sale General Counsel sold 1,646 shares at $2.98 ($4,910)
  5. 4 Grant or award General Counsel acquired 100,000 shares (grant or award)
  6. 4 Open-market sale See Remarks sold 28,918 shares at an average $3.96 ($114,581)
  7. 4 Grant or award Chief Medical Officer acquired 345,911 shares (grant or award)
  8. 4 Grant or award Director acquired 53,333 shares (grant or award)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Option exercise Director acquired 1,100,000 shares (option exercise)
  11. 3 Insider Initial Statement of Ownership
  12. 4 Grant or award See Remarks acquired 40,000 shares (grant or award)
  13. 4 Grant or award General Counsel acquired 150,000 shares (grant or award)
  14. 4 Grant or award See Remarks acquired 80,000 shares (grant or award)
  15. 4 Open-market buy Director bought 10,000 shares at $3.41 ($34,100)
  16. 4 Open-market sale See Remarks sold 1,060 shares at an average $3.04 ($3,224)
  17. 4 Open-market sale See Remarks sold 2,485 shares at an average $3.04 ($7,561)
  18. 4 Open-market sale General Counsel sold 1,592 shares at an average $3.04 ($4,839)
  19. 4 Shares withheld for taxes CEO gave up 2,234 shares (to pay taxes)
  20. 4 Open-market sale See Remarks sold 11,161 shares at $3.02 ($33,695)

Page 3 of 21 · 406 filings